Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Apteeus is currently addressing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity is assigned to a distinct examiner and a distinct art unit. The focus on a distinct art unit indicates that the company's current filings are concentrated within a specific examination group. This concentration suggests that the technical subject matter of the company's patent applications is closely related, falling under the same specialized review criteria within the patent office.
ALISON AZAR HASTINGS is the busiest examiner for the company, overseeing 1 pending office action. This action represents the company's current pending workload. Because the company has a pending office action, the prosecution profile is currently lean. The interaction with the examiner will be the primary factor in determining the success of the company's current efforts to secure patent rights in the Biotechnology & Pharmaceuticals field. Practitioners should monitor the examiner's feedback closely to refine the company's long-term intellectual property strategy and ensure alignment with examination standards.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASTINGS, ALISON AZAR | 1 | 63.5% | +40.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559411 | USE OF CLOFOCTOL FOR THE TREATMENT OF INFLAMMATION | HASTINGS, ALISON AZAR | 75d |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18559411 | USE OF CLOFOCTOL FOR THE TREATMENT OF INFLAMMATION | HASTINGS, ALISON AZAR | 1627 | §103§112DP | Non-Final OA | 75d | Pending | Nov 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial